Navigation Links
Analysis Of Chloramphenicol by Negative Ion Electrospray LC/MS/MS

Z. Yang, Varian, Inc.

Introduction

Chloramphenicol (CAP) is a potent, broad-spectrum antibiotic and potential carcinogen used in humans only at therapeutic doses for treatment of serious infections. Its use in meatproducing animals, food producing insects, aquaculture, and animal-feed products has been banned in the United States, Canada and the European Union. However, the illegal use of CAP remains a possibility due to its broad activity, ready availability, and low cost.

CAP can cause an irreversible illness called aplastic anemia. The incidence rate of aplastic anemia is one out of every 25,000 to 40,000 people. Onset may occur weeks or months after ending treatment with CAP. A very low concentration of CAP may be enough to trigger the illness and the safe level of dosage has not been identified.

Due to known effects of CAP and the recent discovery of CAP in imported food, the U.S. Food and Drug Administration (FDA) and other government agencies throughout the world have increased sampling and surveillance of imported shrimp, crawfish, honey, royal jelly, feed, and milk products for the presence CAP. In addition, the U.S. FDA has developed an LC/MS/MS method to determine CAP in shrimp.1 The detection limit for the method is 80 pg/g* of shrimp, corresponding to 800 fg/μL of the solution injected into the LC/MS.

Instrumentation

Varian ProStar 430 AutoSampler

Varian ProStar 210 Isocratic Solvent Delivery Modules

Varian 1200L LC/MS equipped with ESI source

Materials and Reagents

Chloramphenicol (Part No. C1919) from Sigma-Aldrich Corp. (St. Louis, Missouri, USA).

All other chemicals are reagent grade or HPLC grade.

Results and Discussion

The LC method used a 6 minute run cycle with CAP giving a retention time of 3.1 minutes with a peak width at half height of 0.12 minutes. Both product ions can be quantitatively analyzed at the level of 100 fg/ μL in solution (Figure 1). The linearity of the detector response was found to be excellent (Figure 2). The R2 for 321>152 and 321>257 are 0.999 and 0.998, respectively. In addition, good precision was found at these low levels with RSD (relative standard deviations) of ~6% (Figure 3).

The limit of detection (LOD) is estimated to be <30 fg/μL in solution corresponding to a LOD of <3 pg/g in shrimp according to the U.S. FDA method.

Conclusion

The choice of either product ion for quantitation is especially important when complex matrices interfere with one of the product ions. The Varian 1200L LC/MS/MS system demonstrates excellent sensitivity, reproducibility and performance for the analyses of chloramphenicol and is able to assist in the detection of potentially harmful substance in food imports/ exports to improve food safety throughout the world.

Reference

1. B.K. Neuhaus, J.A. Hurlbut. and W. Hammack LC/MS/MS Analysis of Chloramphenicol in Shrimp. U.S. FDA Laboratory Information Bulletin No. 4290, Volume 18, No. 9, September 2002 .
http://vm.cfsan.fda.gov/~frf/lib4290.html


'"/>

Source:


Page: All 1 2

Related biology technology :

1. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
2. Epitope-Tagging Vectors for Functional Analysis in Yeast
3. Map and Link Human Genetic Disorders with SSLP Analysis
4. CastAway Precast Gels for Rapid Automated DNA Sequence Analysis
5. Single-cell RT-PCR Analysis of Paramecium Primaurelia with the Eppendorf cMaster RTplusPCR System
6. Structural Analysis of Glycosylated Peptides in Complex Mixtures with Ion Trap MSn
7. Use of Transcriptor Reverse Transcriptase in Microarray Analysis
8. Increased Sensitivity in Microarray Analysis
9. Gene-Expression Analysis of TP, DPD, and TS Using the LightCycler mRNA Quantification KitsPLUS
10. Agilent 2100 Bioanalyzer Automated Analysis System
11. Analysis of Microarray Data
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... , Jan. 17, 2017  An international ... of Medicine and St. Boniface Hospital Albrechtsen Research ... peripheral neuropathy, an unmet health need affecting nearly ... Journal of Clinical Investigation, their results identify small ... prevent and reverse neuronal injury in animal models ...
(Date:1/17/2017)... LEXINGTON, Mass. , Jan. 17, 2017   ... clinical stage biopharmaceutical company developing innovative inhaled therapies to ... candidate for treating fungal infections in the lungs of ... Infectious Disease Product" (QIDP) by the U.S. Food & ... , which is designed to speed the development of ...
(Date:1/17/2017)... 17, 2017  Only nine percent of U.S. consumers ... while only 16 percent believe health insurance companies do, ... 36 percent of U.S. adults believe health care providers ... compared to hospitals (23%). "We are in ... Wendy Salomon , vice president of reputation management and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Pono Ola , a mind-body wellness firm ... today the official launch of its much-anticipated Pono Board: a re-invented fitness and anti-fatigue ... development for over a year, the patented Pono Board is the world’s only exercise ...
Breaking Biology Technology:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... -- For the thousands of attendees at this year,s International Consumer Electronics Show ... biometric measurement devices and services, will be featuring its new line of ... Medical,s special CES Exhibit Suite , the new upper arm and ... WellnessConnected product platform.  Continue ... ...
Breaking Biology News(10 mins):